Importer of Controlled Substances Application: Galephar Pharmaceutical Research, Inc., 41065 [2020-14614]

Download as PDF 41065 Federal Register / Vol. 85, No. 131 / Wednesday, July 8, 2020 / Notices personnel will sign appropriate nondisclosure agreements. Controlled substance Authority: These investigations are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.12 of the Commission’s rules. By order of the Commission. Issued: July 1, 2020. Lisa Barton, Secretary to the Commission. Drug code Psilocyn ................... 7438 Schedule I The institute plans to import the listed controlled substances for potential formulation development for substances to be used in institutesponsored research. [FR Doc. 2020–14625 Filed 7–7–20; 8:45 am] BILLING CODE 7020–02–P [FR Doc. 2020–14624 Filed 7–7–20; 8:45 am] Drug Enforcement Administration [Docket No. DEA–680] ACTION: Importer of Controlled Substances Application: Galephar Pharmaceutical Research, Inc. Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 7, 2020. Such persons may also file a written request for a hearing on the application on or before August 7, 2020. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All request for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 21, 2020, Usona Institute, 2780 Woods Hollow Road, Room 2412, Fitchburg, Wisconsin 53711–5370, applied to be registered as an importer of the following basic class(es) of controlled substances: jbell on DSKJLSW7X2PROD with NOTICES DATES: Controlled substance 5-Methoxy-N-Ndimethyltryptamine. Dimethyltryptamine .. Psilocybin ................ VerDate Sep<11>2014 Drug code Schedule ACTION: Notice of application. Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 7, 2020. Such persons may also file a written request for a hearing on the application on or before August 7, 2020. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on June 22, 2020, Galephar Pharmaceutical Research, Inc., 100 Carr 198 Industrial Park, Juncos, Puerto Rico 00777–3873, applied to be registered as an importer of the following basic class(es) of a controlled substance: DATES: 7431 I Controlled substance 7435 7437 I I Hydromorphone ....... 17:17 Jul 07, 2020 Jkt 250001 PO 00000 Frm 00104 Fmt 4703 [Docket No. DEA–681] ACTION: Notice of application. Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before August 7, 2020. Such persons may also file a written request for a hearing on the application on or before August 7, 2020. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on May 28, 2020, Xcelience, 4901 West Grace Street, Tampa, Florida 33607–3805, applied to be registered as an Importer of the following basic class(es) of controlled substances: DATES: [Docket No. DEA–679] Notice of application. BILLING CODE P Importer of Controlled Substances Application: Xcelience DEPARTMENT OF JUSTICE Importer of Controlled Substances Application: Usona Institute [FR Doc. 2020–14614 Filed 7–7–20; 8:45 am] Drug Enforcement Administration BILLING CODE P Drug Enforcement Administration William T. McDermott, Assistant Administrator. DEPARTMENT OF JUSTICE William T. McDermott, Assistant Administrator. DEPARTMENT OF JUSTICE The company plans to import the listed controlled substance in finished dosage form for analytical purpose only. Drug code 9150 Sfmt 4703 Schedule II Controlled substance Psilocybin ................ Amphetamine .......... Drug code 7437 1100 Schedule I II The company plans to import drug code 7437 (Psilocybin), as bulk and drug code 1100 (Amphetamine), as finished dosage form for clinical trials, research, and analytical purposes. No other activity for drug code 1100 is authorized for this registration. Approval of permit E:\FR\FM\08JYN1.SGM 08JYN1

Agencies

[Federal Register Volume 85, Number 131 (Wednesday, July 8, 2020)]
[Notices]
[Page 41065]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-14614]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-679]


Importer of Controlled Substances Application: Galephar 
Pharmaceutical Research, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before August 7, 2020. 
Such persons may also file a written request for a hearing on the 
application on or before August 7, 2020.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All 
requests for a hearing should also be sent to: (1) Drug Enforcement 
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, 
Springfield, Virginia 22152; and (2) Drug Enforcement Administration, 
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, 
Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on June 22, 2020, Galephar Pharmaceutical Research, 
Inc., 100 Carr 198 Industrial Park, Juncos, Puerto Rico 00777-3873, 
applied to be registered as an importer of the following basic 
class(es) of a controlled substance:

------------------------------------------------------------------------
         Controlled substance            Drug code        Schedule
------------------------------------------------------------------------
Hydromorphone.........................        9150  II
------------------------------------------------------------------------

    The company plans to import the listed controlled substance in 
finished dosage form for analytical purpose only.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-14614 Filed 7-7-20; 8:45 am]
BILLING CODE P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.